JP Morgan Chase
LTRN icon

JP Morgan Chase’s Lantern Pharma LTRN Stock Holding History

JP Morgan Chase’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120 Buy
97
+28
+41% +$78 ﹤0.01% 7299
2025
Q4 		$209 Buy
+69
New +$257 ﹤0.01% 7154
2025
Q2 		– Sell
-128
Closed -$453 – 7415
2025
Q1 		$453 Buy
+128
New +$531 ﹤0.01% 6713
2024
Q1 		– Sell
-13
Closed -$56 – 7677
2023
Q4 		$56 Buy
13
+4
+44% +$14 ﹤0.01% 7190
2023
Q3 		$31 Buy
+9
New +$41 ﹤0.01% 7088
2022
Q4 		– Sell
-1,787
Closed -$9K – 6807
2022
Q3 		$9K Sell
1,787
-1,959
-52% -$10.5K ﹤0.01% 5987
2022
Q2 		$21K Sell
3,746
-4,272
-53% -$25.5K ﹤0.01% 5885
2022
Q1 		$57K Buy
8,018
+2,768
+53% +$18.5K ﹤0.01% 5751
2021
Q4 		$42K Buy
+5,250
New +$47.9K ﹤0.01% 6007

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase's LTRN Position: Q1 2026 in Review

JP Morgan Chase increased its Lantern Pharma (LTRN) stake by 41% in Q1 2026, buying an estimated $78 and bringing the position to 97 shares worth $120. The position accounts for ﹤0.01% of the portfolio, ranked #7299.

JP Morgan Chase first reported a position in LTRN in Q4 2021 and has held it in 9 quarters since. The position peaked at $57K in Q1 2022. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • JP Morgan Chase held 97 shares of Lantern Pharma worth $120 as of Q1 2026.
  • JP Morgan Chase bought 28 Lantern Pharma shares in Q1 2026, an estimated $78.
  • Lantern Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7299 holding.
  • JP Morgan Chase first reported a position in Lantern Pharma in Q4 2021 and has held it in 9 quarters since.
  • JP Morgan Chase's Lantern Pharma position peaked at $57K in Q1 2022.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.